Reuters logo
BRIEF-UK regulatory agency approves continued enrollment in Biomarin phase 1/2 study
October 13, 2016 / 8:51 PM / a year ago

BRIEF-UK regulatory agency approves continued enrollment in Biomarin phase 1/2 study

Oct 13 (Reuters) - Biomarin Pharmaceutical Inc

* UK regulatory agency approves continued enrollment in Biomarin phase 1/2 study of BMN 270 in Hemophilia a

* Biomarin Pharmaceutical Inc - Biomarin intends to resume enrollment in phase i/2 study before end of 2016

* Biomarin Pharmaceutical Inc - Safety and efficacy data from these patients will inform phase 2B study planned to begin in second half of 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below